| Species |
Human |
| Protein Construction |
LILRB3/CD85a/ILT5 (Gly24-Glu443)_x000D_
Accession # O75022-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LILRB3/CD85a/ILT5, His & Avi, Human at 5μg/ml (100μl/well) on the plate can bind AntiLILRB3 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-72 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Leukocyte immunoglobulin-like receptor subfamily B (LILRB3), also known as ILT5, LIR3, and CD85a, is an immunoglobulin superfamily member that is involved in immune regulation. Subfamily B members have cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1.LILRB3 may act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. |
| Synonyms |
CD85a; ILT5; ILT-5; LILRB3; LIR3; LIR3CD85A; LIR-3MGC138403; PIRB; HL9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
